Mural Oncology (NASDAQ:MURA) Research Coverage Started at Raymond James

Investment analysts at Raymond James began coverage on shares of Mural Oncology (NASDAQ:MURA) in a research note issued to investors on Friday, MarketBeat.com reports. The brokerage set a “strong-buy” rating and a $18.00 price target on the stock. Raymond James’ price target would suggest a potential upside of 435.71% from the company’s current price.

Separately, Rodman & Renshaw started coverage on Mural Oncology in a research note on Friday, June 28th. They issued a “buy” rating and a $15.00 price target on the stock.

Mural Oncology Trading Up 5.0 %

Shares of NASDAQ:MURA opened at $3.36 on Friday. The company’s fifty day moving average is $3.25 and its 200 day moving average is $3.52. Mural Oncology has a 52 week low of $2.88 and a 52 week high of $17.00.

Mural Oncology (NASDAQ:MURA) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($1.86) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.90) by $0.04. As a group, sell-side analysts forecast that Mural Oncology will post -7.54 EPS for the current fiscal year.

Insider Buying and Selling at Mural Oncology

In other news, CEO Caroline Loew sold 12,531 shares of the stock in a transaction dated Monday, July 8th. The shares were sold at an average price of $2.91, for a total transaction of $36,465.21. Following the completion of the sale, the chief executive officer now directly owns 240,391 shares in the company, valued at approximately $699,537.81. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.06% of the company’s stock.

Hedge Funds Weigh In On Mural Oncology

A number of hedge funds and other institutional investors have recently made changes to their positions in MURA. Acadian Asset Management LLC bought a new stake in Mural Oncology in the second quarter valued at $998,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Mural Oncology in the 2nd quarter worth about $84,000. Armistice Capital LLC bought a new stake in shares of Mural Oncology during the 2nd quarter valued at about $5,300,000. Primecap Management Co. CA purchased a new position in shares of Mural Oncology during the second quarter valued at about $740,000. Finally, Rhumbline Advisers purchased a new position in shares of Mural Oncology during the second quarter valued at about $34,000. Institutional investors own 80.21% of the company’s stock.

About Mural Oncology

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.